Alcon's Acquisition of Belkin Vision: Advancing Laser Technology for Glaucoma Treatment
Saturday, 13 July 2024, 21:56
Alcon Acquires Belkin Vision
Alcon, a global eye care company, has completed the purchase of Israel-based Belkin Vision in a significant deal worth up to $446 million. The acquisition marks a notable advancement in eye care technology.
Cutting-Edge Eagle Laser Technology
Belkin Vision is renowned for its Eagle laser technology, specifically developed for treating glaucoma. This innovative technology, known as direct selective laser trabeculoplasty (DSLT), aims to effectively reduce intraocular pressure without the need for medications, offering a promising alternative for patients.
Importance of Intraocular Pressure Management
- Better Eye Care: Lowering intraocular pressure is crucial in preserving vision and preventing optic nerve damage.
- Medication-Free Solution: DSLT technology provides a non-invasive approach to managing glaucoma.
- Positive Impact: The acquisition of Belkin Vision by Alcon signifies a significant step forward in enhancing eye care treatment options.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.